ACAD — ACADIA PHARMACEUTICALS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1070494 ·
Last close
$18.32
Market Cap
$3.17B
52W High
$30.96
52W Low
$15.86
ADV30
2,381,806
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 342,291,000 307,201,000 71,718,000 53,524,000 1,794,151,000 322,365,000 406,662,000
Jun 2026 307,959,000 279,643,000 37,836,000 31,500,000 1,742,900,000 384,985,000 436,291,000
Mar 2026 268,062,000 243,271,000 -4,616,000 3,637,000 1,605,230,000 282,212,000 357,164,000
Dec 2025 283,989,000 257,764,000 17,391,000 273,568,000 1,564,195,000 177,695,000 336,805,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$97,534,000
Investing CF
$-84,270,000
Financing CF
$49,262,000
CapEx
$-110,767,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.11
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,724,725,000
Inventory
$40,360,000
Receivables
$178,315,000
ST Investments
$654,081,000
EBIT TTM
$122,329,000
Pretax Income TTM
$157,212,000
Interest Exp TTM
—
Analysts
19

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,202,301,056
EBITDA
$135,056,000
Free Cash Flow
$46,267,624
Enterprise Value
$2,764,567,040
Total Cash
$976,446,016
Total Debt
$71,854,000
Shares Out
172,828,972
Trailing EPS
$2.12
Book Value
$8.03
ROE
31.4%
ROA
4.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,071,505,000 104,811,000 391,000,000 1,564,195,000 336,805,000 1,227,390,000 109,836,000
Dec 2024 957,797,000 84,279,000 226,451,000 1,187,756,000 454,963,000 732,793,000 157,719,000
Dec 2023 726,437,000 -73,379,000 -61,286,000 748,956,000 317,201,000 431,755,000 16,702,000
Dec 2022 517,235,000 -223,596,000 -215,975,000 587,812,000 187,399,000 400,413,000 -114,035,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$1,138,643,000
NetIncome TTM
$380,484,000
OpCashFlow TTM
—
Assets (Latest)
$1,742,900,000
Forward EPS
$1.05

Max Pain — expiry 2026-12-18

max pain strike: $20.00 · spot: $17.83 · call oi: 8,316 · put oi: 2,465
Expected Move to 2026-12-18: ±$1.70 (9.53%) — implied range $16.13 – $19.53 · ATM straddle on $18.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BHC Bausch Health Companies Inc. $3.17B $8.47 —
LEGN Legend Biotech Corp $3.13B $16.11 —
BGM BGM Group Ltd. $3.09B $8.13 —
XERS Xeris Biopharma Holdings, Inc. $3.07B $16.80 —
TLX Telix Pharmaceuticals Ltd $3.01B $8.85 —

News headlines (Yahoo Finance, 1h cache)

ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
2026-11-18 03:12 · Yahoo
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease
2026-11-17 14:04 · Yahoo
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
2026-11-16 14:04 · Yahoo
Acadia Pharmaceuticals Fell While Sales Rose
2026-11-10 06:11 · Yahoo
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
2026-11-10 04:47 · Yahoo
Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today
2026-11-10 04:29 · Yahoo
Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?
2026-11-10 01:17 · Yahoo
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
2026-11-09 21:05 · Yahoo
Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says
2026-11-05 17:07 · Yahoo
ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Daybue Sales and ...
2026-11-05 07:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.